Flavonoid-mediated presenilin-1 phosphorylation reduces Alzheimer's disease β-amyloid production
2009
Glycogen synthasekinase 3 (
GSK-3) dysregulation is implicated in the two Alzheimer's disease (AD) pathological hallmarks: β-amyloid plaques and
neurofibrillary tangles.
GSK-3inhibitors may abrogate AD pathology by inhibiting amyloidogenic γ-secretase cleavage of
amyloid precursor protein(APP). Here, we report that the citrus
bioflavonoid
luteolinreduces amyloid-β (Aβ) peptide generation in both human ‘Swedish’ mutant APP transgene-bearing neuron-like cells and primary neurons. We also find that
luteolininduces changes consistent with
GSK-3inhibition that (i) decrease amyloidogenic γ-secretase APP processing, and (ii) promote
presenilin-1 (PS1) carboxyl-terminal fragment (CTF) phosphorylation. Importantly, we find GSK-3α activity is essential for both PS1 CTF phosphorylation and PS1-APP interaction. As validation of these findings in vivo, we find that
luteolin, when applied to the Tg2576 mouse model of AD, decreases soluble Aβ levels, reduces
GSK-3activity, and disrupts PS1-APP association. In addition, we find that Tg2576 mice treated with
diosmin, a glycoside of a flavonoid structurally similar to
luteolin, display significantly reduced Aβ pathology. We suggest that
GSK-3inhibition is a viable therapeutic approach for AD by impacting PS1 phosphorylation-dependent regulation of amyloidogenesis.
Keywords:
-
Correction
-
Source
-
Cite
-
Save
66
References
100
Citations
NaN
KQI